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Neurobiology of Disease
An Epilepsy-Associated SV2A Mutation Disrupts
Synaptotagmin-1 Expression and Activity-Dependent
Trafficking
Callista B. Harper,1,2,3 Christopher Small,4 Elizabeth C. Davenport,1,2,3 Darryl W. Low,1,2 Karen J. Smillie,1,2
Ramón Martínez-Mármol,4 Frédéric A. Meunier,4 and Michael A. Cousin1,2,3
1Centre for Discovery Brain Sciences, Hugh Robson Building, University of Edinburgh, Edinburgh, EH8 9XD, United Kingdom, 2Muir Maxwell
Epilepsy Centre, University of Edinburgh, Edinburgh EH8 9XD, United Kingdom, 3Simons Initiative for the Developing Brain, University of
Edinburgh, Edinburgh EH8 9XD, United Kingdom, and 4Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The
University of Queensland, Brisbane, Queensland QLD 4072, Australia
The epilepsy-linked gene SV2A, has a number of potential roles in the synaptic vesicle (SV) life cycle. However, how loss of
SV2A function translates into presynaptic dysfunction and ultimately seizure activity is still undetermined. In this study, we
examined whether the first SV2A mutation identified in human disease (R383Q) could provide information regarding which
SV2A-dependent events are critical in the translation to epilepsy. We utilized a molecular replacement strategy in which ex-
ogenous SV2A was expressed in mouse neuronal cultures of either sex, which had been depleted of endogenous SV2A to
mimic the homozygous human condition. We found that the R383Q mutation resulted in a mislocalization of SV2A from
SVs to the plasma membrane, but had no effect on its activity-dependent trafficking. This SV2A mutant displayed reduced
mobility when stranded on the plasma membrane and reduced binding to its interaction partner synaptotagmin-1 (Syt1).
Furthermore, the R383Q mutant failed to rescue reduced expression and dysfunctional activity-dependent trafficking of Syt1
in the absence of endogenous SV2A. This suggests that the inability to control Syt1 expression and trafficking at the presy-
napse may be key in the transition from loss of SV2A function to seizure activity.
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Significance Statement
SV2A is a synaptic vesicle (SV) protein, the absence or dysfunction of which is linked to epilepsy. However, the series of molecu-
lar events that result in this neurological disorder is still undetermined. We demonstrate here that the first human mutation in
SV2A identified in an individual with epilepsy displays reduced binding to synaptotagmin-1 (Syt1), an SV protein essential for
synchronous neurotransmitter release. Furthermore, this mutant cannot correct alterations in both Syt1 expression and traffick-
ing when expressed in the absence of endogenous SV2A (to mimic the homozygous human condition). This suggests that the
inability to control Syt1 expression and trafficking may be key in the transition from loss of SV2A function to seizure activity.
Introduction
SV2A is a multitransmembrane synaptic vesicle (SV) protein, the
dysfunction of which is linked to epilepsy via a series of inde-
pendent observations (Mendoza-Torreblanca et al., 2013;
Ciruelas et al., 2019). First, SV2A is the binding target of the
leading anti-epileptic drug levetiracetam (Lynch et al., 2004).
Second, deletion of the Sv2a gene in mice results in severe seiz-
ures and lethality after two to threeweeks (Crowder et al., 1999;
Janz et al., 1999). Third, rats harboring a missense mutation in
SV2A (L174Q) display increased seizure susceptibility (Tokudome
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et al., 2016a,b). Finally, a homozygous mutation in the SV2A gene
in an individual with intractable epilepsy (R383Q) was identified
(Serajee and Huq, 2015). Therefore, evidence is accumulating that
loss of SV2A function plays a key role in precipitating seizure ac-
tivity. However, it is still unclear how SV2A dysfunction translates
into epilepsy.
SV2A is proposed to perform multiple roles at the presynapse
(Mendoza-Torreblanca et al., 2013; Ciruelas et al., 2019). One
role is as an intrinsic trafficking partner (iTRAP) during SV
endocytosis (Gordon and Cousin, 2016). The efficient endocyto-
sis of SVs is essential for maintenance of neurotransmission at
central nerve terminals (Chanaday et al., 2019). A series of cargo
capture and clustering mechanisms ensure that SVs possess the
correct complement of membrane cargo with the correct stoichi-
ometry. SV cargos are clustered by adaptor protein complexes
such as AP-2 and/or monomeric adaptor proteins such as AP180
and stonin-2 (Kelly and Owen, 2011; Koo et al., 2011, 2015;
Kononenko et al., 2013). In addition, SV cargos called iTRAPs
share interactions with specific SV proteins to ensure a high fi-
delity of retrieval during endocytosis (Yao et al., 2010; Gordon et
al., 2011; Kaempf et al., 2015; Zhang et al., 2015). SV2A is an
iTRAP for synaptotagmin-1 (Syt1; Gordon and Cousin, 2016),
which is an essential protein for coupling calcium influx to neu-
rotransmitter release (Geppert et al., 1994).
Loss of SV2A function, either via shRNA knock-down
(Kaempf et al., 2015; Zhang et al., 2015) or genetic deletion (Yao
et al., 2010) has specific effects on Syt1 function. First, the re-
trieval of Syt1 during endocytosis is accelerated (Kaempf et al.,
2015; Zhang et al., 2015). Second, the expression of Syt1 is
reduced, especially on SVs (Yao et al., 2010; Kaempf et al., 2015).
SV2A interacts with the calcium-binding C2B domain of Syt1 at
its cytoplasmic N terminus (Schivell et al., 1996, 2005). This
interaction is triggered by the phosphorylation of a specific resi-
due (T84) within the SV2A N terminus by casein family kinases
(Pyle et al., 2000; Zhang et al., 2015). Mutagenesis of this phos-
phorylation site ablates Syt1 binding and renders mutant SV2A
protein unable to rescue the phenotypes described above (Zhang
et al., 2015).
We used a neuronal system in which endogenous SV2A
was depleted and replaced with SV2A containing the R383Q
mutation to mimic the homozygous human condition. We
found that this mutation increased the surface localization of
SV2A, and reduced its surface mobility without affecting its
activity-dependent trafficking. Furthermore, the R383Q mu-
tant displayed reduced binding to Syt1. This resulted in a
lack of rescue of Syt1 expression and activity-dependent Syt1
retrieval kinetics. This association between a human SV2A
mutant and a loss of control of Syt1 function suggests that
the latter may be the key epileptogenic step in mammalian
systems.
Materials and Methods
Materials
Unless otherwise specified, all tissue culture reagents were obtained
from Invitrogen. Fetal bovine serum (FBS) was from Biosera. Papain
was obtained fromWorthington. Nitrocellulose membranes and mo-
lecular weight markers were from Bio-Rad. Tetrodotoxin citrate
(TTX) was from Hello Bio. Primary antibodies were purchased from
Abcam unless otherwise specified. All other reagents were obtained
from Sigma-Aldrich.
Syt1-pHluorin was a gift from Prof. Volker Haucke (Leibniz-Institute
for Molecular Pharmacology). SV2A-pHluorin, SV2A-mCerulean, and
pSUPER vectors that co-express SV2A shRNA (shRNA sequence
GAATTGGCTCAGCAGTATG) with either mCerulean or Syt1-pHluorin
were described previously (Zhang et al., 2015). Y46A and R383Q muta-
tions were introduced into human SV2A-pHluorin using the following
primers (mutated bases underlined; Y46A forward, GCATCCAGT
GATGCTGCTGAGGGCCATGACGAG; Y46A reverse, CTCGTCAT
GGCCCTCAGCAGCATCACTGGATGC; R383Q forward, CATGATA
CCAACATGCAAGCCAAAGGACATCCT; R383Q reverse, AGGATG
TCCTTTGGCTTGCATGTTGGTATCATG). The R383Q mutation was
introduced into SV2A-mCerulean using the primers: forward, CACGA
CACCAACATGCAAGCCAAGGCCCACCCT; reverse, AGGGTGGC
CCTTGGCTTGCATGTTGGTGTCGTG. Wild-type and R383Q SV2A-
mCerulean were made shRNA resistant using the primers: forward,
GAGCTTGCGCAGCAATAC; reverse, GTATTGCTGCGCAAGCTC.
Syt1-HA in a pCMV5 vector (DU38472) was obtained from the MRC-
PPU (University of Dundee). A glutathione S-transferase (GST) fusion
protein of the third cytoplasmic loop of SV2A (amino acids 356–447) was
generated by amplifying DNA encoding this region from SV2A-
mCerulean using the primers (forward, GGATCCGAGAGTCCCCG
CTTCTTCCTAGAGA; reverse, CTCGAGTCACGTGATGCGCCGATA
CTCTGGACTG) and ligating into a PGEX-4T-1 vector using the
enzymes BamHI and XhoI (underlined). The R383Q mutation was
introduced using identical primers to those described above for
SV2A-mCerulean.
Animal maintenance
Animal work was performed in accordance with the UK Animal
(Scientific Procedures) Act 1986, under Project and Personal License
authority and was approved by the Animal Welfare and Ethical Review
Body at the University of Edinburgh (Home Office project license 70/
8878). Specifically, all animals were killed by schedule 1 procedures in
accordance with United Kingdom Home Office Guidelines; adults were
killed by cervical dislocation followed by decapitation, whereas embryos
were killed by decapitation followed by destruction of the brain. Wild-
type C57BL/6J mice were sourced from an in-house colony at the
University of Edinburgh. All mouse colonies were housed in standard
open top caging on a 14/10 h light/dark cycle (light 7 A.M. to 9 P.M.).
Breeders were fed RM1 chow, whereas stock mice were maintained on
RM3 chow.
For single particle tracking experiments, animal work was performed
in accordance with the Australian Code and Practice for the Care and
Use of Animals for Scientific Purposes and approved by the University
of Queensland Animal Ethics Committee (QBI/254/16/NHMRC).
Animals were housed with 12/12 h light/dark exposure (light 7 A.M. to 7
P.M.) and fed with autoclaved mouse and rat cubes (Specialty Feeds).
Mice were culled by cervical dislocation and embryos were euthanized
by decapitation.
Primary neuronal culture and transfection
Dissociated primary hippocampal enriched neuronal cultures were pre-
pared from embryonic day (E)16.5–E18.5 embryos from wild-type C57/
BL6J mice of both sexes as outlined (Zhang et al., 2015; Harper et al.,
2017). In brief, isolated hippocampi were digested in 10 U/ml papain in
Dulbecco’s PBS, washed in minimal essential medium (MEM) supple-
mented with 10% FBS, and triturated to single cell suspension. This cell
suspension was plated at 3–5 104 cells on poly-D-lysine and laminin-
coated 25-mm coverslips. Cells were transfected on 7–9 d in vitro (DIV)
with Lipofectamine 2000 as per manufacturer’s instructions (Gordon
and Cousin, 2013).
For single particle tracking experiments, dissection and culture were
performed as outlined (Joensuu et al., 2017). Briefly, embryos of both
sexes were dissected in 1 HBSS, 10 mM HEPES (pH 7.3), 100 U/ml
penicillin, and 100mg/ml streptomycin. Hippocampal tissue was
digested with 0.25% trypsin. Digestion was halted by addition of 5% FBS
and DNase I. Cell suspension was triturated, centrifuged (120  g,
7min) and resuspended in Neurobasal Medium, 100 U/ml penicillin,
100mg/ml streptomycin, 1 GlutaMAX supplement, 1 B27, and 5%
FBS. Neurons were seeded in poly-L-lysine-coated 29-mm glass-bottom
dishes (Cellvis) at a density of 1 105 neurons. A full media change was
performed 2–4 h after seeding using culturing media (Neurobasal
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Medium, 100 U/ml penicillin, 100mg/ml streptomycin, 1 GlutaMAX
supplement, and 1 B27). Cells were transfected at DIV 14–15 with
Lipofectamine 2000 as per manufacturer’s instructions.
Immunostaining
Cultured hippocampal neurons were washed once with PBS before fixa-
tion in 4% paraformaldehyde, quenching by 50 mM NH4Cl and perme-
abilization with 0.1% v/v Triton X-100, 1% w/v bovine serum albumin
(BSA) in PBS. Cultured neurons were blocked with 1% BSA in PBS
before incubation with primary antibodies: chicken anti-GFP (ab13970,
1:10,000), rabbit anti-SV2A (ab13259, 1:500), and mouse anti-Syt1
(ab32942, 1:500). Rabbit anti-synaptophysin (#101002, 1:1000) was from
Synaptic Systems. The cultures were washed with PBS and incubated
with fluorescently conjugated secondary antibodies [goat anti-chicken
Alexa Fluor 488 (Life Technologies, A11039), goat anti-rabbit Alexa
Fluor 555 A21430, goat anti-mouse Alexa Fluor 647 A21235, and goat
anti-rabbit Alexa Fluor 647 A21244; all 1:500). The coverslips were
mounted on slides for imaging with FluorSave (Millipore).
Fluorescence imaging
Imaging was conducted on a Zeiss Axio Observer D1 or Z1/7 inverted epi-
fluorescence microscope with a Zeiss EC Plan Neofluar 40/1.30 oil
immersion objective. Images were captured using an AxioCam 506 mono
camera (Zeiss). GFP/pHluorin or mCerulean vectors were visualized at ei-
ther 500- or 430-nm excitation respectively (long-pass emission filter
.520nm). Alexa Fluor 488 and 555 labeled coverslips were imaged simul-
taneously using double band pass excitation filters (470/27nm1 556/
25nm) and emission filters 512/30 and 630/98nm (Zeiss). Alexa Fluor
647 fluorescence was acquired with band pass excitation (640/30nm) and
emission filters 690/50nm (Zeiss).
For live-cell imaging, hippocampal cultures were mounted in a
Warner Instruments imaging chamber with embedded parallel platinum
wires (RC-21BRFS). Cultures were stimulated with a train of 300 action
potentials delivered at 10Hz (100mA, 1-ms pulse width) during which
there was continuous perfusion of imaging buffer (119 mM NaCl, 2.5 mM
KCl, 2 mM CaCl2, 2 mM MgCl2, 30 mM D-glucose, 25 mM HEPES; pH
7.4 supplemented with 10mM 6-cyano-7-nitroquinoxaline-2,3-dione and
50 mM DL-2-amino-5-phosphonopentanoic acid). After 180 s cultures
were perfused with alkaline imaging buffer (50 mM NH4Cl substituted
for 50 mM NaCl) to reveal total pHluorin fluorescence. Fluorescent
images were captured at 4-s intervals throughout.
Plasma membrane-localized pHluorin reporters were revealed by
bathing neurons in imaging buffer, and then perfusing with acidic imag-
ing buffer (2-(N-morpholino)ethanesulfonic acid substituted for HEPES,
pH 5.5) to quench surface fluorescence and retain background auto-flu-
orescence. Neurons were washed in imaging buffer and subsequently
exposed to alkaline imaging buffer to reveal the total fluorescent signal.
Where indicated, TTX (200 nM) was added to culture medium 72 h
before imaging to block neuronal activity.
Imaging analysis
Offline data processing was performed using Fiji is just ImageJ (Fiji)
software (Schindelin et al., 2012). For live-cell imaging, a script based on
background thresholding was used to select nerve terminals, which
placed regions of interest of identical size over those responding to stim-
ulation. Average fluorescent intensity was measured over time using the
time series analyzer plugin before screening regions of interest using a
customized Java program that allows for visualization of the fluorescent
responses and removal of aberrant traces from the data. Fixed cell
images were analyzed by placing regions of interest of identical size over
nerve terminals of transfected and untransfected cells and measuring the
average fluorescent intensity in each channel. Transfected nerve termi-
nals were normalized to measurements from surrounding untransfected
neurons.
All subsequent data analyses were performed using Microsoft Excel,
MATLAB, and GraphPad Prism 6.0 software. The change in activity-de-
pendent pHluorin fluorescence was calculated as F/F0 and normalized to
the peak of stimulation. The percentage of pHluorin molecules visiting
the plasma membrane during action potential stimulation was calculated
as F/F0, and then expressed as a percentage of the pHluorin response in
the presence of NH4Cl. The fraction of pHluorin reporter at the plasma
membrane was expressed as a percentage of total pHluorin and was cal-
culated using the following equation: [(basal fluorescence – acidic fluo-
rescence)/(alkaline fluorescence – acidic fluorescence)] 100.
Super-resolution microscopy
Neurons transfected with either wild-type or R383Q SV2A-pHluorin
were used 1–5 d post-transfection. Transfected neurons were imaged at
50Hz and 20-ms exposure (16,000 frames) at 37°C on a Roper Scientific
Ring-TIRF microscope with a CPI Apo 100/1.49N.A. oil-immersion
objective (Nikon Instruments). The microscope was equipped with
Evolve 512 d EMCCD cameras (Photometrics), a Perfect Focus System
(Nikon Instruments), an iLas2 double laser illuminator (Roper
Scientific), a quadruple beam splitter (ZT405/488/561/647rpc; Chroma
Technology), and a QUAD emission filter (ZET405/488/561/640m;
Chroma Technology).
Single particle tracking of surface molecules
Single plasma membrane SV2A molecules were imaged by performing
Universal Point Accumulation Imaging in Nanoscale Topography
(uPAINT; Giannone et al., 2010; Joensuu et al., 2017) on hippocampal
neurons (DIV 15–20) in oblique illumination configuration. For
uPAINT imaging, neurons were bathed in low KCl buffer (0.5 mM
MgCl2, 2.2 mM CaCl2, 5.6 mM KCl, 145 mM NaCl, 5.6 mM D-glucose, 0.5
mM ascorbic acid, 0.1% BSA, and 15 mM HEPES; pH 7.4) and placed on
the microscope. Following identification of transfected nerve terminals,
low KCl buffer was replaced with stimulation buffer (substituted NaCl
for KCl giving final concentrations of 56 mM KCl and 95 mM NaCl) con-
taining 3.19pg ml1 anti-GFP Atto647N-tagged nanobodies (Synaptic
Systems). Image acquisition was initiated during stimulation using a 642
nM laser to excite the nanobodies. Processing and analysis were con-
ducted in PALMTracer 1, a custom written program that functions in
MetaMorph (Molecular Devices; Kechkar et al., 2013; Nair et al., 2013).
Regions of interest were drawn around nerve terminals of hippocampal
axons based on pHluorin fluorescence unquenching during stimulation.
The spatial detection limit was set to 0.106mm. Mean square displace-
ment (MSD) was calculated from reconstructed trajectories lasting a
minimum of eight frames. The equation MSD(t) = a1 4Dt (where D =
diffusion coefficient, a is y intercept, and t is time) was used to fit MSD.
Trajectories were divided into mobile and immobile populations and a
diffusion coefficient of log10 . 1.45 mm2 s1 was considered as mobile
(Constals et al., 2015; Joensuu et al., 2016).
Protein expression and GST-pull downs
Isolated nerve terminals (synaptosomes) from rat brain of either sex
were prepared as described previously (Cousin and Robinson, 2000).
GST fusion proteins were expressed in bacteria, lysed using sonication in
the buffer (150 mM NaCl, 1 mM EDTA, 10% Triton X-100, 1.5% sarcosyl,
8mg lysozyme, 1 mM PMSF, protease inhibitor cocktail, 5 mM dithio-
threitol, and 10 mM Tris; pH 7.4) and then coupled to glutathione-
sepharose beads (Anggono et al., 2006). Synaptosomes were solubilized
for 5min at 4°C in 25 mM Tris (pH 7.4), containing 1% Triton X-100,
150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1 mM PMSF, and protease in-
hibitor cocktail. Lysates were centrifuged at 20,442  g for 5min at 4°C
with the supernatant retained. Supernatants were incubated with GST-
fusion proteins for 1 h at 4°C to allow binding. After a series of washes
in lysis buffer (including a wash in high-salt buffer, lysis buffer supple-
mented with 500 mM NaCl), beads were washed twice in 20 mM Tris
(pH 7.4) and then boiled in SDS sample buffer. The released proteins
separated by SDS-PAGE (12.5%) for subsequent analysis by Western
blotting.
Co-immunoprecipitation from HEK cell cultures
HEK293 cells were maintained in culture media (MEM; Invitrogen,
41966-029), 10% FBS, and 1% penicillin/streptomycin) at 37°C in 5%
CO2 humidified atmosphere. Cells were trypsinized (1 trypsin-EDTA,
Invitrogen, 15400-054) and seeded into fresh 10-cm dishes 24 h before
transfection with Lipofectamine 2000 as per manufacturer’s instructions.
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After transfection (48 h), cells were solubilized in 0.5 ml HEPES buffer
for 1 h [50 mM HEPES (pH 7.5), 0.5% Triton X-100, 150 mM NaCl, 1
mM EDTA, 1 mM PMSF, and protease inhibitor cocktail) and centrifuged
at 17,000  g for 10min to pellet the cell debris. Supernatant was col-
lected then incubated with 10ml of a 50% slurry of GFP TRAP beads
(Chromotech) under rotation at 4°C for 2 h. Beads were washed three
times with HEPES buffer before being incubated in SDS sample buffer at
65°C for 10min to avoid SV2A protein aggregation. Samples were then
analyzed by SDS-PAGE andWestern blotting.
Western blotting
Western blotting was performed as described previously (Anggono
et al., 2006). Primary antibodies used were anti-GFP rabbit (ab6556,
1:4000) and anti-HA rabbit (ICLlab, RHGT-45A-Z, 1:20,000) or
rabbit anti-Syt1 (Synaptic Systems, #105103, 1:5000). IRDye second-
ary antibodies [800CW anti-rabbit IgG (#925-32213, 1:10,000);
680RD anti-rabbit IgG (#926-68071, 1:10,000), and Odyssey block-
ing PBS buffer (#92740000)] were from LI-COR Biosciences. Blots
were visualized using a LiCOR Odyssey fluorescent imaging system
(LiCOR Biotechnology). Band densities were determined using
LiCOR Image Studio Lite software (version 5.2). GST pulldown
samples were analyzed by normalizing the density of the Western
blotting bands to the density of GST fusion protein band revealed by
Ponceau-S staining. For co-immunoprecipitations, the amount
Syt1-HA co-immunoprecipitated was normalized to the amount of
input protein. These values were then normalized to the amount of
immunoprecipitated SV2A-mCerulean.
Statistical analysis
Statistical analysis was performed in Graph Pad Prism 6.0. A Student’s t
test was used to compare differences between two groups, whereas a
one-way ANOVA with a Tukey’s post hoc test was used to compare
more than two groups. In all analyses, the sample size (n) was taken to
be the number of independent experiments or individual coverslips. All
data are presented as mean values6 SEM.
Results
The R383Q mutation does not affect SV2A expression at
nerve terminals
Loss of SV2A in mice results in seizure activity and early lethality
(Crowder et al., 1999; Janz et al., 1999). It also disrupts the traf-
ficking and expression of Syt1 (Yao et al., 2010; Kaempf et al.,
2015; Zhang et al., 2015). Whether these two outcomes of SV2A
dysfunction are linked is still unknown. The identification of a
patient with intractable epilepsy possessing a homozygous muta-
tion (R383Q) in SV2A (Serajee and Huq, 2015) provides the op-
portunity to address this question directly.
Figure 1. The R383Q mutation does not affect SV2A expression. Primary cultures of hip-
pocampal neurons were transfected with shRNA against SV2A and either an empty vector
(mCerulean, mCer), wild-type (WT) SV2A-mCer or R383Q SV2A-mCer after 7–9 DIV. After
13–15 DIV, neurons were fixed and immunostained for both GFP and SV2A. A, Example images
are displayed, with GFP in green and SV2A in red. White arrowheads indicate transfected nerve
terminals. Scale bar = 10mm. B, Quantification of SV2A expression was performed by deter-
mining the intensity of SV2A signal in transfected synapses relative to untransfected synapses
in the same field of view (n =12 mCer, n=14 WT, n= 12 R383Q coverslips from three inde-
pendent preparations, one-way ANOVA, ***p, 0.001, ns = not significant).
Figure 2. SV2A R383Q is mislocalized from SVs. Primary cultures of hippocampal neurons
were transfected with either wild-type or R383Q SV2A-pHluorin and either empty mCer vec-
tor or shRNA against SV2A 7–8 d before image acquisition (DIV 13–15). Cultures were
sequentially perfused with acidic then NH4Cl imaging buffer, interspersed with control imag-
ing buffer. A, Example images are displayed from neurons expressing both SV2A shRNA and
SV2A-pHluorin with pseudo-coloring to indicate regions of high fluorescent intensity in con-
trol (Baseline), acidic (Acid), and NH4Cl imaging buffer. Scale bar = 10mm. B, C, The propor-
tion of SV2A-pHluorin on the plasma membrane as a percentage of the total pool is
presented 6SEM in the presence (B) or absence (C) of endogenous SV2A [B; n= 14 wild-
type (WT) and R383Q, C; n= 15 WT, n =19 R383Q, cells from three independent prepara-
tions, Student’s t test, **p= 0.003 for B, **p= 0.008 for C].
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We first determined whether the
R383Q mutation resulted in altered
expression of SV2A at nerve terminals in
primary cultures of hippocampal neu-
rons. To determine this, endogenous
SV2A was depleted using shRNA and
co-expressed with either shRNA-resist-
ant wild-type or R383Q SV2A tagged
with the fluorescent protein mCerulean
(mCer; Fig. 1A). Expression of shRNA
against SV2A resulted in a significant
depletion of SV2A at nerve terminals
when compared with untransfected
controls (Fig. 1B; one-way ANOVA,
p, 0.0001), as observed previously
(Zhang et al., 2015). Co-expression of
wild-type SV2A-mCer restored expression
to approximately two-fold that of endoge-
nous levels (Fig. 1B; one-way ANOVA,
p, 0.0001). Similar values were also
observed for R383Q SV2A-mCer, indicat-
ing that this mutation does not alter SV2A
expression at nerve terminals (Fig. 1B;
one-way ANOVA, not significant).
The R383Qmutation increases SV2A
plasma membrane stranding
We next determined whether the R383Q
mutation affected the localization of SV2A
at nerve terminals. To do so, we exploited
SV2A-pHluorin, a genetically-encoded re-
porter that provides information on the
pH of its local environment due to a pH-
sensitive GFP fused to a lumenal loop of
SV2A (Zhang et al., 2015). In resting neu-
rons, SV2A-pHluorin is only fluorescent
when present at the plasma membrane,
since its fluorescence is quenched within
the acidic SV interior. Therefore, exposure
to an impermeant acidic solution can
reveal the proportion of SV2A on the
plasma membrane. The extent of surface
SV2A-pHluorin can then be expressed as
a proportion of the total pool by de-acidi-
fying SVs with an ammonium chloride so-
lution (Fig. 2A; Gordon et al., 2011;
Zhang et al., 2015).
When expressed in wild-type neu-
rons, the plasma membrane localization
of SV2A-pHluorin was low (6.36 0.6% of total; Fig. 2B), in
agreement with previous studies (Pan et al., 2015). In contrast,
R383Q SV2A-pHluorin displayed an approximate two-fold
increase (10.56 1.2% of total; Fig. 2B, Student’s t test, p=0.003).
When either wild-type or R383Q SV2A-pHluorin were
expressed in neurons which had endogenous SV2A depleted
using shRNA (to mimic the homozygous condition), the pro-
portion of surface R383Q SV2A-pHluorin was still significantly
increased (Fig. 2C, Student’s t test, p= 0.008). Therefore, the
R383Q mutation results in mislocalization of SV2A from SVs
to the plasma membrane in neurons that were either depleted
of, or contained, endogenous SV2A.
To gain additional insight into the increased surface stranding
of R383Q SV2A, we determined whether this mutation resulted
in altered SV2A mobility at the plasma membrane using the sin-
gle molecule super-resolution microscopy technique, uPAINT
(Giannone et al., 2010; Joensuu et al., 2017). Neurons transfected
with either wild-type or R383Q SV2A-pHluorin were imaged
during stimulation in the presence of anti-GFP Atto647N nano-
bodies (Fig. 3A). Single-particle tracking analysis was performed
to generate high-resolution mean intensities, diffusion coeffi-
cients, and single-molecule trajectory maps of either wild-type or
R383Q SV2A–pHluorin (Fig. 3B–F). No significant differences
in the MSD (Fig. 3D, Student’s t test, p=0.5) and number of
detected trajectories per synapse of R383Q SV2A-pHluorin-
atto647-NB mobility (Fig. 3F, Student’s t test, p=0.2) was
observed compared with wild type. However, a difference in the
mobile:immobile ratio was detected, with the R383Q SV2A-
pHluorin displaying a lower mobility than wild type (Fig. 3E,
Figure 3. The R383Q mutation impacts the plasma membrane mobility of SV2A at nerve terminals. Primary cultures of hip-
pocampal neurons were transfected with either wild-type or R383Q SV2A-pHluorin at 14–15 DIV. After 1–5 d post-transfection,
neurons were stimulated 50 mM KCl. A, Representative panels depicting presynaptic SV2A-pHluorin fluorescence in addition to
diffusion coefficient, intensity, and tracks of SV2A-pHluorin wild-type (WT; n= 15) and R383Q (n= 12;.3 independent prepa-
rations). Scale bar = 1mm. B, MSD of SV2A-pHluorin-atto647N-nanobodies (NB). C, Frequency distribution of log10 of diffusion
coefficient [D] (mm2 s1). D, Area under the curve (AUC; mm2  100) for MSD of SV2A-pHluorin (WT/R383Q) shown in B. E,
Mobile:immobile ratio (M/MM) for frequency distribution shown in C. F, Number of trajectories of wild-type and R383Q SV2A-
pHluorin (n= 12 neurons) per synapse. Values are represented as mean6 SEM. Statistical comparisons were performed using
a paired Student’s t test. No significant differences detected between AUC of MSD (D; ns, p= 0.50) and detections per synapse
(F; *p= 0.20) for SV2A-pHluorin WT and R383Q. Significant difference observed between WT and R383Q mutant for the mo-
bile:immobile ratio (E; ns, p= 0.037).
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Student’s t test, p=0.038). In the diffusion coefficient maps (Fig.
3A), regions highlighted in warmer colors are associated with
tracks of low mobility, which were more prominent for SV2A-
R383Q-pHluorin relative to SV2A-WT-pHluorin. Taken together,
this suggests that the R383Q mutation reduces SV2A mobility on
the plasma membrane, potentially via increased clustering.
Increased plasma membrane localization of SV proteins
can be indicative of defective retrieval during endocytosis.
Therefore, we next determined whether
the R383Q mutation disrupted SV2A
retrieval during endocytosis in SV2A-
depleted neurons. The activity-depend-
ent trafficking of SV2A-pHluorin can
be detected as an increase in fluores-
cence on stimulation due to exocytosis
(since the reporter encounters the neutral
extracellular environment; Fig. 4A). After
stimulation terminates, the kinetics of the
fluorescence decay reflects the kinetics of
SV2A-pHluorin retrieval, since endocyto-
sis is rate limiting when compared with
SV acidification (Atluri and Ryan,
2006; Granseth et al., 2006; but also see
Egashira et al., 2015). When neurons
expressing wild-type SV2A-pHluorin
were challenged with a train of action
potentials (300 at 10Hz), a characteris-
tic peak and fluorescent decay was observ-
ed (Fig. 4B). An identical response was
observed for R383Q SV2A-pHluorin (Fig.
4B). An absence of effect of the R383Q
mutation on SV2A retrieval was con-
firmed when the proportion of pHluorin
reporter remaining on the plasma mem-
brane after stimulation was quantified
(Fig. 4C, Student’s t test, p= 0.917).
Furthermore, the R383Q mutation had
no effect on the number of SV2A-
pHluorin molecules visiting the plasma
membrane during stimulation (wild type,
53.16 3.4%; 53.66 3.9% of total SV2A-
pHluorin, Student’s t test, p=0.91), indi-
cating an absence of effect on SV exocyto-
sis. Thus, the R383Q mutation results in a
mislocalization of SV2A from SVs to the
plasma membrane, but had no effect
on its retrieval during endocytosis.
Importantly, this also indicates that the
R383Q mutation does not affect endocy-
tosis in general, since any disruption
would be reflected in altered SV2A-
pHluorin retrieval kinetics.
To confirm that the increased propor-
tion of the R383Q mutant residing at the
plasma membrane was not due to defects
in its activity-dependent retrieval, we
examined the effect of silencing neuronal
activity. This maneuver typically corrects
surface stranding defects that are a result
of activity-dependent cargo retrieval
(Kaempf et al., 2015). Neuronal activity
was silenced via application of the so-
dium channel antagonist TTX for 72 h.
Neuronal silencing had no effect on the
proportion of wild-type SV2A-pHluorin at the plasma mem-
brane (Fig. 4D, Student’s t test, p= 0.375). In contrast, an inter-
nalization defective SV2A mutant (Y46A; Yao et al., 2010)
displayed a reduced plasma membrane localization in TTX-
treated cultures when compared with control (Fig. 4D, Student’s
t test, p=0.046). Finally, silencing of neuronal activity had no
effect on the mislocalization of R383Q SV2A-pHluorin (Fig. 4D,
Figure 4. Mislocalization of R383Q SV2A is not due to an activity-dependent trafficking defect. A–C, Primary cultures of hip-
pocampal neurons were transfected with both SV2A-pHluorin (wild-type or R383Q) and shRNA against SV2A after 7–8 DIV.
After 13–15 DIV neurons were stimulated with a train of 300 action potentials delivered at 10 Hz. The neurons were allowed
to recover before being pulsed with NH4Cl imaging buffer to reveal the total SV2A-pHluorin population. A, Representative
images are displayed in at specific time points indicated, with responsive nerve terminals highlighted using arrowheads. Scale
bar = 10mm. B, Traces display the time course of the average fluorescent SV2A-pHluorin response normalized to the peak of
stimulation. Bar indicates the period of stimulation. C, SV2A-pHluorin remaining to be retrieved 130 s after termination of stim-
ulation is displayed as F/F0 6SEM (for B, C, n= 13 neurons from three independent preparations, displayed6SEM, Student’s
t test, ns, p= 0.917). D, Primary cultures of hippocampal neurons were transfected with mCerulean and either wild-type,
Y46A, or R383Q SV2A-pHluorin at 7 DIV. Neurons were treated with either vehicle (Veh) or TTX (200 nM) at 11 DIV for 72 h.
Cultures then sequentially perfused with acidic and NH4Cl imaging buffer, interspersed with control imaging buffer. The propor-
tion of SV2A-pHluorin on the plasma membrane expressed as a percentage of the total pool normalized to the control condi-
tion 6SEM is displayed (n= 14–17 cells from four independent preparations, Student’s t test, ns, p= 0.375 WT, *p= 0.046
Y46A, ns, p= 0.716 R383Q).
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Student’s t test, p=0.716). This confirmed that
the increased plasma membrane localization of
the R383Q mutant was not due to defective ac-
tivity-dependent retrieval.
The R383Qmutation disrupts SV2A binding
to Syt1
SV2A interacts with the C2B domain of Syt1
via its N terminus in a phosphorylation-de-
pendent manner (Schivell et al., 1996, 2005;
Pyle et al., 2000; Zhang et al., 2015). This inter-
action controls a series of Syt1-specific func-
tions in neurons (Ciruelas et al., 2019). The
R383Q mutation resides on a large cytoplasmic
loop that is distal from the SV2A N terminus in
terms of its primary sequence (Fig. 5A).
However, due to the key role SV2A performs in
the control of Syt1 function, we assessed the
impact of the R383Q mutation on this
interaction.
First, we determined whether the cytoplas-
mic loop of SV2A in which the R383Q muta-
tion resides interacts with Syt1. To achieve this,
we generated a GST-fusion protein encompass-
ing this loop (residues 356–447; Fig. 5A) with
which we attempted to extract Syt1 from nerve
terminal lysates. Pull-down experiments were
performed using either GST alone, wild-type
GST-SV2A356–447 or the equivalent R383Q mu-
tant. Western blotting revealed that neither
wild-type nor the R383Q mutant was able to
extract Syt1 from nerve terminal lysates that
had either been challenged with or without ele-
vated KCl (Fig. 5B). Therefore, the third cyto-
plasmic loop of SV2A is not sufficient to bind Syt1.
We next examined whether the R383Q mutation affected the
ability of full-length SV2A to interact with Syt1 in a heterologous
expression system. Both SV2A-mCer and HA-tagged Syt1 were
co-expressed in HEK cells with SV2A-mCer subsequently immu-
noprecipitated using an anti-GFP nanobody. Wild-type SV2A-
mCer co-immunoprecipitated HA-Syt1, whereas no HA-Syt1
was present in immunoprecipitates from cells expressing mCer
alone (Fig. 5C,D). R383Q SV2A-mCer was able to co-immuno-
precipitate HA-Syt1, however, at a significantly reduced level
(Fig. 5D, Student’s t test, p=0.0035). Therefore, the R383Q
mutation results in a decreased ability of SV2A to interact with
Syt1.
The R383Qmutation disrupts the expression and activity-
dependent trafficking of Syt1
The reduced interaction of Syt1 with the R383Q mutant form of
SV2A suggests that it may alter Syt1 function in the absence of en-
dogenous SV2A. We first determined whether R383Q SV2A-
mCer affected the synaptic expression of Syt1 in SV2A-depleted
neurons (Fig. 6A). Knock-down of SV2A reduced endogenous
Syt1 levels below that of untransfected controls, using synaptophy-
sin as a presynaptic marker (Fig. 6B; Yao et al., 2010; Kaempf et
al., 2015). Conversely, rescue of expression with wild-type SV2A-
mCer produced a significant increase in endogenous Syt1 expres-
sion when compared with SV2A-depleted neurons (Fig. 6B, one-
way ANOVA, p=0.0002). In contrast, expression of R383Q
SV2A-mCer was unable to restore endogenous Syt1 expression to
these levels (Fig. 6B, one-way ANOVA, p=0.007). Therefore, the
R383Q mutant has lost the ability to regulate Syt1 expression at
nerve terminals.
Loss of SV2A results in an acceleration of activity-dependent
Syt1-pHluorin retrieval during endocytosis (Kaempf et al., 2015;
Zhang et al., 2015). Therefore, we next determined whether the
R383Q mutation could rescue Syt1 retrieval kinetics in SV2A-
depleted neurons (Fig. 7A). Depletion of SV2A with shRNA
resulted in an acceleration of Syt1-pHluorin retrieval, a phenotype
that was rescued by wild-type SV2A-mCer (Fig. 7B,C, one-way
ANOVA, p=0.0348). In contrast, expression of R383Q SV2A-
mCer was unable to rescue normal Syt1-pHluorin retrieval
kinetics (Fig. 7B,C, one-way ANOVA, p=0.0473). Therefore, the
R383Qmutation results in a version of SV2A that has lost the abil-
ity to control the retrieval of Syt1 during neuronal activity.
Discussion
Loss of SV2A function is linked to epilepsy, since mice that are
null for the gene exhibit lethal seizure activity (Crowder et al.,
1999; Janz et al., 1999). However, it is still unclear how loss of
SV2A function translates into seizures. To investigate this, we
examined the effect of expressing a human SV2A mutant linked
to epilepsy in primary neuronal cultures that were depleted of
endogenous SV2A to determine which presynaptic events were
altered. We found that the R383Q mutation caused mislocaliza-
tion of SV2A from SVs to the plasma membrane in a manner in-
dependent of neuronal activity. The mutation reduced the ability
of SV2A to bind to Syt1, and failed to correct defects in the
expression and activity-dependent trafficking of Syt1. This links
inaccurate control of Syt1 function by SV2A with seizure genera-
tion and epilepsy.
Figure 5. SV2A R383Q displays reduced binding to Syt1. A, Diagram depicts SV2A in the SV membrane with the
cytoplasmic loop fused to GST highlighted in purple. B, Glutathione beads coupled to either GST alone, wild-type
(WT) GST-SV2A356–447 or R383Q GST-SV2A356–447 were used to extract interaction partners from nerve terminal
lysates which had previously been challenged with or without 30 mM KCl. A representative western blot is displayed
for Syt1 in addition to Ponceau staining to reveal GST fusion proteins. Synaptosome lysates (Syns) were also present
as a positive control (representative of five independent experiments). C, D, HA-tagged Syt1 was co-expressed with
either mCerulean empty vector (mCer), WT SV2A-mCer or R383Q SV2A-mCer in HEK cells. Immunoprecipitation of
mCer was performed from cell lysates. C, Representative western blots displaying the amount of SV2A, Syt1, or
mCer present in either the input (2.5%) or immunoprecipitate. D, Quantification of the amount of HA-Syt1 co-immu-
noprecipitated (co-IP) was normalized to the amount of SV2A-mCer6SEM (n= 7, Student’s t test, **p= 0.0035).
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SV2A is one of the most efficiently targeted proteins to SVs,
with only ;5% present at the plasma membrane in resting neu-
rons (Pan et al., 2015). This is similar to the vesicular glutamate
transporter, whereas other cargoes such as synaptophysin, synap-
tobrevin-II and Syt1 have a higher baseline level of surface local-
ization (Gordon et al., 2011; Kononenko et al., 2013; Kaempf et
al., 2015; Pan et al., 2015; Zhang et al., 2015; Harper et al., 2017).
The activity-independent increase in surface stranding of the
R383Q mutant is intriguing, suggesting that mislocalization
results from either an increased retention at the plasma mem-
brane or loss from SVs via an unidentified mechanism. The
decrease in the ratio of mobile:immobile SV2A R383Qmolecules
suggests the former possibility. SV2A molecules stranded on the
plasma membrane have a similar mobility to synaptobrevin-II
(Joensuu et al., 2016, 2017), suggesting that the organization of
these vesicular proteins at the nanoscale level might be dynami-
cally regulated. Both the increased retention of R383Q SV2A and
altered nanoclustering may occur via enhanced interactions with
integral plasma membrane proteins or the presynaptic cytos-
keletal network. These cell surface phenotypes may not be critical
to the epilepsy presented in this individual however, since the
mutant appears to behave in a loss of function manner.
To replicate the homozygous human condition in which the
R383Q mutation was identified (Serajee and Huq, 2015) experi-
ments were performed in neurons where endogenous SV2A was
depleted. In this regard, knock-down of endogenous SV2A expres-
sion was very efficient (Zhang et al., 2015) and rescue of expres-
sion by either shRNA-resistant wild-type or R383Q SV2A-mCer
did not exceed a two-fold increase over endogenous levels, ensur-
ing a close approximation to the disease context. Coincidentally, a
new heterozygous missense mutation in the SV2A gene has
recently been identified in a child and mother with epilepsy
(Wang et al., 2019). The mutation (R570C) is located within the
large intraluminal loop of SV2A, a region that when mutated can
result in defective SV2A trafficking (Ciruelas et al., 2019). This
heterozygous mutation is likely to be dominant, since only the
homozygous R383Q mutation results in loss of function (Serajee
and Huq, 2015), however it should be noted that haploinsufficient
SV2A mice display increased lethality compared with wild type
(Crowder et al., 1999; Janz et al., 1999).
Figure 7. SV2A R383Q cannot rescue Syt1 retrieval kinetics in SV2A-depleted cells.
Primary cultures of hippocampal neurons were transfected with a bicistronic vector express-
ing Syt1-pHluorin (Syt1-pH) and shRNA against SV2A and either mCerulean (mCer), wild-
type (WT) SV2A-mCer, or R383Q SV2A-mCer after 7–8 DIV. At 13–15 DIV, neurons were
stimulated with a train of 300 action potentials delivered at 10 Hz. Neurons were allowed to
recover before being pulsed with NH4Cl imaging buffer reveal the total Syt1-pH population.
A, Representative images are displayed at specific time points indicated, with responsive
nerve terminals highlighted using arrowheads. Scale bar = 10mm. B, Traces display the
time course of the average fluorescent Syt1-pHluorin response normalized to the peak of
stimulation. Bar indicates the period of stimulation (n= 7 for mCer and n= 11 for both WT
and R383Q SV2A-mCer, from four independent preparations). C, Syt1-pHluorin remaining to
be retrieved 130 s after termination of stimulation is displayed as F/F0 6SEM (one-way
ANOVA, *p= 0.0348 WT compared with mCer, p= 0.0473 WT compared with R383Q SV2A-
mCer, ns = not significant, mCer compared with R383Q).
Figure 6. SV2A R383Q cannot rescue Syt1 expression in SV2A-depleted cells. Cultured hip-
pocampal neurons were transfected with SV2A shRNA and either an empty vector
(mCerulean, mCer), wild-type (WT) SV2A-mCer, or R383Q SV2A-mCer at 7–9 DIV. After 13–
15 DIV, neurons were fixed and immunostained for GFP, Syt1, and Synaptophysin (Syp). A,
Representative images are displayed with arrowheads highlighting transfected nerve termi-
nals (identified using Syp immunostaining). Scale bar = 10mm. B, Quantification of Syt1
expression at nerve terminals is displayed, with the signal from transfected synapses normal-
ized to untransfected synapses in the same field of view6 SEM (n = 12 mCer, n= 14 WT,
n= 14 R383Q cells from three independent preparations, one-way ANOVA, ***p= 0.0002,
**p= 0.007, ns = not significant).
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SV2A binds adenine nucleotides within its third cytoplasmic
loop, with the R383Q mutation residing at the extreme periphery
of one of the potential interaction motifs (Yao and Bajjalieh,
2008). This binding is not related to ATP transport per se, and
has been proposed to alter the ability of SV2A to interact with
other proteins (Ciruelas et al., 2019). Regardless, altered adenine
nucleotide binding is unlikely to be responsible for our observed
effects, since binding is still retained when the region containing
R383 is deleted (Yao and Bajjalieh, 2008). The R383Q mutation
does result in a decreased interaction between SV2A and Syt1,
however the cytoplasmic loop containing the mutation is not suf-
ficient to bind Syt1. Therefore, this loop may modulate binding
via the SV2A N terminus, which contains Syt1 interaction sites
(Schivell et al., 1996, 2005; Zhang et al., 2015).
The R383Q mutation had no effect on the activity-dependent
trafficking of SV2A. Furthermore, it had no global effect on SV
exocytosis or endocytosis. The absence of effect on SV endocyto-
sis has been observed by different groups (Yao et al., 2010;
Kaempf et al., 2015; Zhang et al., 2015), suggesting the major
role of SV2A is to coordinate Syt1 expression and trafficking.
The ability of SV2A to interact with Syt1 appears to be central in
the control of its function, since the R383Q mutant displayed a
marked inability to rescue either Syt1 expression or activity-de-
pendent Syt1 retrieval. This is also true for the T84A SV2A mu-
tant (C.H., unpublished observations), which cannot interact
with Syt1 (Zhang et al., 2015). Therefore, we propose that the
primary defect of the R383Q mutation is the reduction in Syt1
binding, which results in decreased Syt1 expression and traffick-
ing. The failure of the R383Q mutant to rescue these functions
suggests that these may be interlinked, e.g., lower levels of Syt1
may result in its more efficient retrieval. If this is the case, then
the primary dysfunction caused by the decreased interaction of
SV2A with Syt1 is the control of Syt1 expression. Testing
whether Syt1 retrieval kinetics are affected by reducing its
expression is complex however, since monitoring trafficking
using Syt1-pHluorin will also increase Syt1 levels.
The patient carrying the homozygous R383Q mutation dis-
played early developmental delay, including microcephaly,
growth retardation and severe hypotonia within six months
(Serajee and Huq, 2015). Seizures were reported at twomonths,
and were subsequently refractory to medication. Recently, a
Syt1-specific disorder has been identified, named Baker–Gordon
syndrome (Baker et al., 2018). Patients with Baker–Gordon syn-
drome display hypotonia, hyperkinetic movement disorders, and
developmental delay, which range from moderate to profound.
All patients have heterozygous missense mutations in the calcium-
binding C2B domain of Syt1, resulting in reduced SV fusion
kinetics (Baker et al., 2015, 2018). Importantly, no patient dis-
played epileptic seizures. The absence of seizures in Baker–
Gordon patients suggests that Syt1 dysfunction is not sufficient for
epilepsy, but rather the decrease in the trafficking or expression of
Syt1 in the absence of functional SV2A may be key. It will be criti-
cal for future studies to investigate the interplay between these two
important SV proteins in both the physiological and pathologic
context.
A link between SV2A dysfunction and seizure activity is well
established. For example, postmortem samples from patients
with temporal lobe epilepsy displayed reduced SV2A expression
in the hippocampus, a finding mirrored in rodent models of sta-
tus epilepticus (van Vliet et al., 2009). Furthermore, SV2A
knock-out mice display lethal seizure activity after three weeks
(Crowder et al., 1999; Janz et al., 1999) and rats expressing a
spontaneous missense mutation in SV2A display increased
seizure susceptibility (Tokudome et al., 2016a,b). Importantly,
both of these model systems displayed a reduction in Syt1
expression across the whole brain of ;50% (Yao et al., 2010;
Tokudome et al., 2016b). Furthermore, SVs purified from SV2A/
B double knock-out mice displayed an 85% reduction in Syt1
(Yao et al., 2010). Therefore, there is a good correlation between
the reduction in Syt1 expression and seizure activity in rodents
with dysfunctional or absent SV2A.
How may seizure activity originate? One potential mecha-
nism is from the combination of reduced Syt1 expression and its
further reduction on SVs. This depletion may only affect neurons
that fire at high frequencies, such as inhibitory interneurons,
(Bartos et al., 2007), due to an increased demand for efficient
Syt1 trafficking from an already reduced pool of Syt1 molecules.
Importantly, SV2A is the primary paralog in GABAergic neu-
rons (Ciruelas et al., 2019) and expression of SV2A is higher in
GABAergic neurons when compared with glutamatergic neurons
(Tokudome et al., 2016a,b). In addition, rats expressing a sponta-
neous missense mutation in SV2A display a defect in the evoked
release of GABA, but not glutamate (Tokudome et al., 2016a,b).
Therefore, since GABAergic interneurons fire at higher frequen-
cies they may experience an exacerbated depletion of Syt1 from
SVs, whereas most neurons may be able to function normally.
The loss of Syt1 from GABAergic SVs may result in a reduction
in the rate, extent or synchronicity of SV fusion events. This may
culminate in a loss of inhibitory drive in specific circuits, result-
ing in seizure activity.
In conclusion, we have demonstrated that a missense muta-
tion in SV2A that results in human epilepsy is unable to rescue
defects in Syt1 function when expressed in its disease-related
context. This strongly suggests that dysregulation of Syt1 func-
tion may be responsible for the seizure activity observed due to
loss of SV2A function.
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